1. Home
  2. BACQ vs MXCT Comparison

BACQ vs MXCT Comparison

Compare BACQ & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BACQ
  • MXCT
  • Stock Information
  • Founded
  • BACQ 2024
  • MXCT 1999
  • Country
  • BACQ United States
  • MXCT United States
  • Employees
  • BACQ N/A
  • MXCT N/A
  • Industry
  • BACQ
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • BACQ
  • MXCT Health Care
  • Exchange
  • BACQ NYSE
  • MXCT Nasdaq
  • Market Cap
  • BACQ 333.2M
  • MXCT 361.8M
  • IPO Year
  • BACQ 2024
  • MXCT 2021
  • Fundamental
  • Price
  • BACQ $10.03
  • MXCT $2.61
  • Analyst Decision
  • BACQ
  • MXCT Strong Buy
  • Analyst Count
  • BACQ 0
  • MXCT 2
  • Target Price
  • BACQ N/A
  • MXCT $10.00
  • AVG Volume (30 Days)
  • BACQ 211.0K
  • MXCT 647.8K
  • Earning Date
  • BACQ 01-01-0001
  • MXCT 05-07-2025
  • Dividend Yield
  • BACQ N/A
  • MXCT N/A
  • EPS Growth
  • BACQ N/A
  • MXCT N/A
  • EPS
  • BACQ N/A
  • MXCT N/A
  • Revenue
  • BACQ N/A
  • MXCT $38,627,000.00
  • Revenue This Year
  • BACQ N/A
  • MXCT $9.05
  • Revenue Next Year
  • BACQ N/A
  • MXCT $19.98
  • P/E Ratio
  • BACQ $111.40
  • MXCT N/A
  • Revenue Growth
  • BACQ N/A
  • MXCT N/A
  • 52 Week Low
  • BACQ $9.80
  • MXCT $2.21
  • 52 Week High
  • BACQ $10.07
  • MXCT $5.26
  • Technical
  • Relative Strength Index (RSI)
  • BACQ N/A
  • MXCT 41.72
  • Support Level
  • BACQ N/A
  • MXCT $2.29
  • Resistance Level
  • BACQ N/A
  • MXCT $2.74
  • Average True Range (ATR)
  • BACQ 0.00
  • MXCT 0.23
  • MACD
  • BACQ 0.00
  • MXCT 0.04
  • Stochastic Oscillator
  • BACQ 0.00
  • MXCT 68.97

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: